Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2042533 | 0.98 | SLC6A2 (0.45) | SLC6A2MMP12MMP13 | |
| SCHEMBL22797134 | 0.83 | SLC6A2 (0.51) | SLC6A2MMP12MMP13 | |
| SCHEMBL19615422 | 0.81 | SLC6A2 (0.45) | SLC6A2MMP12MMP13 | |
| SCHEMBL22899941 | 0.78 | SLC6A2 (0.31) | SLC6A2MMP12MMP13 | |
| SCHEMBL20001453 | 0.76 | SLC6A2 (0.46) | SLC6A2MMP12MMP13 | |
| SCHEMBL2020872 | 0.75 | TSHR (0.35) | SLC6A2MMP12MMP13 | |
| SCHEMBL28140457 | 0.74 | DGAT1 (0.35) | SLC6A2MMP12MMP13 | |
| SCHEMBL5538 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL28317233 | 0.72 | DGAT1 (0.34) | — | |
| SCHEMBL16842554 | 0.72 | CA2 (0.38) | SLC6A2MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088087-B | Tetrahydropyridine derivatives and their use as antibacterial agents | 东亚ST株式会社 | 2022-08-09 | — | — | CN | claimed |
| EP-3344609-A1 | ANTIBACTERIAL HETEROCYCLIC DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-11 | — | — | EP | claimed |
| EP-3341378-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-04 | — | — | EP | claimed |
| EP-3143007-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2017-03-22 | — | — | EP | claimed |
| WO-2017037039-A1 | ANTIBACTERIAL HETEROCYCLIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | claimed |
| WO-2017036968-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | claimed |
| EP-3114126-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Actelion Pharmaceuticals Ltd (CH) | 2017-01-11 | — | — | EP | claimed |
| EP-3044211-A1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd (CH) | 2016-07-20 | — | — | EP | claimed |
| WO-2015173329-A1 | ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-19 | — | — | WO | claimed |
| WO-2015132228-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-11 | — | — | WO | claimed |
| WO-2015036964-A1 | ANTIBACTERIAL 2H-INDAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-03-19 | — | — | WO | claimed |
| EP-2683689-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc (US) | 2014-01-15 | — | — | EP | claimed |
| WO-2012120397-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | WO | claimed |
| CN-110088087-B | Tetrahydropyridine derivatives and their use as antibacterial agents | 东亚ST株式会社 | 2022-08-09 | — | — | CN | disclosed |
| EP-3344630-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-09 | — | — | EP | disclosed |
| CN-108026100-B | Substituted 1, 2-dihydro-3H-pyrrolo [1,2-c ] imidazol-3-one antibacterial agents | 爱杜西亚药品有限公司 | 2020-09-18 | — | — | CN | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011073845-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | SLC6A2 4624/4885MMP12 482/4885MMP13 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.